{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:09:03Z","timestamp":1786118943628,"version":"build-2736575974"},"reference-count":61,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,5]]},"abstract":"<jats:p>Heart transplantation for patients with end-stage heart failure refractory to medical therapy has remained definitive treatment with significant advances in posttransplant care. Despite improvement in postoperative morbidity and mortality, acute cellular rejection (ACR) and antibody-mediated rejection (AMR) remain substantial challenges that can lead to allograft failure and patient mortality. Immunosuppressive agents have been the mainstay of both prevention and treatment for ACR and AMR; however, many challenges exist with traditional therapies. There are a multitude of molecular pathways involved in mediating the humoral and cellular response to rejection, offering various targets for treatment. This review summarizes therapies used in the management of ACR and AMR as extrapolated from use in induction therapy and treatment of other solid-organ transplant rejection. Future studies focused on cardiac transplant recipients are needed to expand therapeutic options.<\/jats:p>","DOI":"10.1097\/crd.0000000000000596","type":"journal-article","created":{"date-parts":[[2023,8,2]],"date-time":"2023-08-02T09:02:04Z","timestamp":1690966924000},"page":"193-198","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Cardiac Allograft Rejection: Strategies for Success in the Face of Immune Challenges"],"prefix":"10.1097","volume":"33","author":[{"given":"Haris","family":"Patail","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, University of Connecticut School of Medicine, CT"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shazli","family":"Khan","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Westchester Medical Center, New York Medical College, NY."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chhaya","family":"Aggarwal-Gupta","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Westchester Medical Center, New York Medical College, NY."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wilbert S.","family":"Aronow","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Westchester Medical Center, New York Medical College, NY."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2023,8,2]]},"reference":[{"key":"R2-20250404","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.healun.2009.01.015","article-title":"Asymptomatic antibody-mediated rejection after heart transplantation predicts poor outcomes.","volume":"28","author":"Wu","year":"2009","journal-title":"J Heart Lung Transplant"},{"key":"R4-20250404","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1016\/j.healun.2021.07.021","article-title":"The International Thoracic Organ Transplant Registry of the International Society for Heart and Lung Transplantation: Thirty-eighth adult lung transplantation report - 2021; Focus on recipient characteristics.","volume":"40","author":"Chambers","year":"2021","journal-title":"J Heart Lung Transplant"},{"key":"R5-20250404","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1016\/j.healun.2011.08.003","article-title":"The registry of the international society for heart and lung transplantation: twenty-eighth adult heart transplant report\u20142011.","volume":"30","author":"Stehlik","year":"2011","journal-title":"J Heart Lung Transplant"},{"key":"R6-20250404","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.surge.2010.11.023","article-title":"Cardiac allograft rejection.","volume":"9","author":"Patel","year":"2011","journal-title":"Surgeon"},{"key":"R7-20250404","doi-asserted-by":"crossref","first-page":"841849","DOI":"10.3389\/fimmu.2022.841849","article-title":"Assessment of acute rejection by global longitudinal strain and cardiac biomarkers in heart-transplanted patients.","volume":"13","author":"Clemmensen","year":"2022","journal-title":"Front Immunol"},{"key":"R8-20250404","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1016\/j.healun.2018.07.022","article-title":"The international thoracic organ transplant registry of the international society for heart and lung transplantation: thirty-fifth adult heart transplantation report-2018; focus theme: multiorgan transplantation.","volume":"37","author":"Khush","year":"2018","journal-title":"J Heart Lung Transplant"},{"key":"R9-20250404","doi-asserted-by":"crossref","first-page":"3171","DOI":"10.1016\/j.transproceed.2004.10.048","article-title":"Incidence of acute cellular rejection and non-cellular rejection in cardiac transplantation.","volume":"36","author":"Subherwal","year":"2004","journal-title":"Transplant Proc"},{"key":"R10-20250404","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1161\/CIR.0000000000000093","article-title":"Antibody-mediated rejection in cardiac transplantation: emerging knowledge in diagnosis and management: a scientific statement from the American Heart Association.","volume":"131","author":"Colvin","year":"2015","journal-title":"Circulation"},{"key":"R11-20250404","doi-asserted-by":"crossref","first-page":"3858","DOI":"10.1161\/01.CIR.0000150332.42276.69","article-title":"Drug therapy in the heart transplant recipient: part II: immunosuppressive drugs.","volume":"110","author":"Lindenfeld","year":"2004","journal-title":"Circulation"},{"key":"R12-20250404","doi-asserted-by":"crossref","first-page":"5785","DOI":"10.4049\/jimmunol.1390055","article-title":"Calcineurin inhibitors: 40 years later, can\u2019t live without.","volume":"191","author":"Azzi","year":"2013","journal-title":"J Immunol"},{"key":"R13-20250404","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1016\/j.healun.2010.05.034","article-title":"The International Society of Heart and Lung Transplantation Guidelines for the care of heart transplant recipients.","volume":"29","author":"Costanzo","year":"2010","journal-title":"J Heart Lung Transplant"},{"key":"R14-20250404","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s00467-008-1020-x","article-title":"Mechanism of cellular rejection in transplantation.","volume":"25","author":"Ingulli","year":"2010","journal-title":"Pediatr Nephrol"},{"key":"R15-20250404","first-page":"180","article-title":"Failing Heart Transplants and Rejection-A Cellular Perspective.","volume":"8","author":"Hurskainen","year":"2021","journal-title":"J Cardiovasc Dev Dis"},{"key":"R16-20250404","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1016\/j.jcmg.2009.06.006","article-title":"The role of multimodality cardiac imaging in the transplanted heart.","volume":"2","author":"Estep","year":"2009","journal-title":"JACC Cardiovasc Imaging"},{"key":"R17-20250404","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1111\/tri.12284","article-title":"Acute cellular rejection the first year after heart transplantation and its impact on survival: a single-centre retrospective study at Sk\u00e5ne University Hospital in Lund 1988-2010.","volume":"27","author":"S\u00f6derlund","year":"2014","journal-title":"Transpl Int"},{"key":"R18-20250404","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1136\/jcp.2005.026443","article-title":"An approach to endomyocardial biopsy interpretation.","volume":"59","author":"Cunningham","year":"2006","journal-title":"J Clin Pathol"},{"key":"R19-20250404","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.healun.2021.01.1564","article-title":"Clinical utility of donor-derived cell-free DNA testing in cardiac transplantation.","volume":"40","author":"Khush","year":"2021","journal-title":"J Heart Lung Transplant"},{"key":"R20-20250404","doi-asserted-by":"crossref","first-page":"2889","DOI":"10.1111\/ajt.15339","article-title":"Noninvasive detection of graft injury after heart transplant using donor-derived cell-free DNA: a prospective multicenter study.","volume":"19","author":"Khush","year":"2019","journal-title":"Am J Transplant"},{"key":"R21-20250404","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1016\/j.healun.2005.03.019","article-title":"Revision of the 1990 working formulation for the standardization of nomenclature in the diagnosis of heart rejection.","volume":"24","author":"Stewart","year":"2005","journal-title":"J Heart Lung Transplant"},{"key":"R22-20250404","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1016\/j.healun.2005.03.018","article-title":"The revised ISHLT heart biopsy grading scale.","volume":"24","author":"Billingham","year":"2005","journal-title":"J Heart Lung Transplant"},{"key":"R24-20250404","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.trre.2008.08.004","article-title":"Antibody-mediated rejection: treatment alternatives and outcomes.","volume":"23","author":"Singh","year":"2009","journal-title":"Transplant Rev"},{"key":"R25-20250404","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.healun.2005.09.003","article-title":"Acute antibody-mediated rejection of cardiac transplants.","volume":"25","author":"Reed","year":"2006","journal-title":"J Heart Lung Transplant"},{"key":"R26-20250404","first-page":"876","article-title":"Platelet transfusions are associated with the development of anti-major histocompatibility complex class I antibodies in patients with left ventricular assist support.","volume":"17","author":"Moazami","year":"1998","journal-title":"J Heart Lung Transplant"},{"key":"R27-20250404","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1016\/j.healun.2011.02.015","article-title":"The ISHLT working formulation for pathologic diagnosis of antibody-mediated rejection in heart transplantation: evolution and current status (2005\u20132011).","volume":"30","author":"Berry","year":"2011","journal-title":"J Heart Lung Transplant"},{"key":"R29-20250404","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1111\/ajt.12162","article-title":"A survey of current practice for antibody-mediated rejection in heart transplantation.","volume":"13","author":"Chih","year":"2013","journal-title":"Am J Transplant"},{"key":"R30-20250404","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.healun.2009.10.016","article-title":"Controversies in defining cardiac antibody-mediated rejection: need for updated criteria.","volume":"29","author":"Kfoury","year":"2010","journal-title":"J Heart Lung Transplant"},{"key":"R31-20250404","first-page":"46","article-title":"Antibody-mediated rejection: a review.","volume":"17","author":"Garces","year":"2017","journal-title":"Ochsner J"},{"key":"R32-20250404","doi-asserted-by":"crossref","first-page":"S254","DOI":"10.1016\/j.healun.2013.01.658","article-title":"Clinical and echocardiographic presentation of rejection episodes following heart transplantation.","volume":"32","author":"Sudini","year":"2013","journal-title":"J Heart Lung Transplant"},{"key":"R33-20250404","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1111\/tri.12480","article-title":"Thymoglobulin induction in heart transplantation: patient selection and implications for maintenance immunosuppression.","volume":"28","author":"Zuckermann","year":"2015","journal-title":"Transpl Int"},{"key":"R34-20250404","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1016\/j.healun.2008.07.002","article-title":"Induction therapy with thymoglobulin after heart transplantation: impact of therapy duration on lymphocyte depletion and recovery, rejection, and cytomegalovirus infection rates.","volume":"27","author":"Goland","year":"2008","journal-title":"J Heart Lung Transplant"},{"key":"R35-20250404","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1038\/sj.leu.2404683","article-title":"Mechanisms of action of antithymocyte globulin: T-cell depletion and beyond.","volume":"21","author":"Mohty","year":"2007","journal-title":"Leukemia"},{"key":"R36-20250404","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.trim.2007.05.001","article-title":"The type of ATG matters -- natural killer cells are influenced differentially by Thymoglobulin, Lymphoglobulin and ATG-Fresenius.","volume":"18","author":"Penack","year":"2007","journal-title":"Transpl Immunol"},{"key":"R37-20250404","first-page":"319","article-title":"Thymoglobulin \u2013 new approaches to optimal outcomes.","volume":"2","author":"Moiceanu","year":"2009","journal-title":"J Med Life"},{"key":"R38-20250404","first-page":"901","article-title":"Low-dose rituximab therapy for antibody-mediated rejection in a highly sensitized heart-transplant recipient.","volume":"39","author":"Aggarwal","year":"2012","journal-title":"Tex Heart Inst J"},{"key":"R39-20250404","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1111\/ctr.12277","article-title":"Rituximab is associated with improved survival in cardiac allograft patients with antibody-mediated rejection: a single center review.","volume":"27","author":"Ravichandran","year":"2013","journal-title":"Clin Transplant"},{"key":"R40-20250404","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1016\/j.healun.2004.09.003","article-title":"Treatment of vascular rejection with rituximab in cardiac transplantation.","volume":"24","author":"Garrett","year":"2005","journal-title":"J Heart Lung Transplant"},{"key":"R41-20250404","doi-asserted-by":"crossref","first-page":"e002790","DOI":"10.1161\/JAHA.115.002790","article-title":"Comparison of basiliximab and anti-thymocyte globulin as induction therapy in pediatric heart transplantation: a survival analysis.","volume":"5","author":"Ansari","year":"2016","journal-title":"J Am Heart Assoc"},{"key":"R42-20250404","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.healun.2007.01.006","article-title":"Basiliximab and rabbit anti-thymocyte globulin for prophylaxis of acute rejection after heart transplantation: a non-inferiority trial.","volume":"26","author":"Carrier","year":"2007","journal-title":"J Heart Lung Transplant"},{"key":"R43-20250404","doi-asserted-by":"crossref","DOI":"10.1111\/ctr.13132","article-title":"Low-dose basiliximab induction therapy in heart transplantation.","volume":"31","author":"Kittipibul","year":"2017","journal-title":"Clin Transplant"},{"key":"R44-20250404","doi-asserted-by":"crossref","first-page":"207","DOI":"10.2165\/00003495-199957020-00006","article-title":"Basiliximab.","volume":"57","author":"Onrust","year":"1999","journal-title":"Drugs"},{"key":"R45-20250404","doi-asserted-by":"crossref","first-page":"S278","DOI":"10.1016\/j.healun.2014.01.739","article-title":"Efficacy and Safety of Basiliximab as Curative Treatment of Persistent or Complicated Acute Rejection in Cardiac Transplantation.","volume":"33","author":"Bouregaa","year":"2014","journal-title":"J Heart Lung Transplant"},{"key":"R46-20250404","doi-asserted-by":"crossref","first-page":"344","DOI":"10.7182\/pit2012241","article-title":"Alemtuzumab for cytolytic induction of immunosuppression in heart transplant recipients.","volume":"22","author":"Cahoon","year":"2012","journal-title":"Prog Transplant"},{"key":"R47-20250404","doi-asserted-by":"crossref","first-page":"3723","DOI":"10.1016\/j.transproceed.2018.08.044","article-title":"Acute cellular rejection and infection rates in alemtuzumab vs traditional induction therapy agents for lung and heart transplantation: a systematic review and meta-analysis.","volume":"50","author":"Li","year":"2018","journal-title":"Transplant Proc"},{"key":"R48-20250404","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.healun.2007.11.569","article-title":"Alemtuzumab (Campath-1H) induction in a pediatric heart transplant: successful outcome and rationale for its use.","volume":"27","author":"Das","year":"2008","journal-title":"J Heart Lung Transplant"},{"key":"R49-20250404","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1177\/1074248419841635","article-title":"Alemtuzumab induction versus conventional immunosuppression in heart transplant recipients.","volume":"24","author":"Gale","year":"2019","journal-title":"J Cardiovasc Pharmacol Ther"},{"key":"R50-20250404","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1016\/j.healun.2007.04.012","article-title":"Alemtuzumab (Campath 1H) as successful salvage therapy for recurrent steroid-resistant heart transplant rejection.","volume":"26","author":"Woodside","year":"2007","journal-title":"J Heart Lung Transplant"},{"key":"R51-20250404","doi-asserted-by":"crossref","DOI":"10.1111\/petr.12844","article-title":"Alemtuzumab (Campath-1H) therapy for refractory rejections in pediatric heart transplant recipients.","volume":"21","author":"Das","year":"2017","journal-title":"Pediatr Transplant"},{"key":"R52-20250404","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.healun.2015.10.009","article-title":"Alemtuzumab as a novel treatment for refractory giant cell myocarditis after heart transplantation.","volume":"35","author":"Evans","year":"2016","journal-title":"J Heart Lung Transplant"},{"key":"R54-20250404","doi-asserted-by":"crossref","first-page":"147","DOI":"10.7182\/pit2015934","article-title":"Bortezomib-containing regimen for primary treatment of early antibody-mediated cardiac allograft rejection: a case report.","volume":"25","author":"Gazdic","year":"2015","journal-title":"Prog Transplant"},{"key":"R55-20250404","doi-asserted-by":"crossref","first-page":"e14907","DOI":"10.1111\/ctr.14907","article-title":"Efficacy of bortezomib desensitization among heart transplant candidates.","volume":"37","author":"Brinkley","year":"2023","journal-title":"Clin Transplant"},{"key":"R56-20250404","doi-asserted-by":"crossref","first-page":"3692","DOI":"10.1016\/j.transproceed.2006.10.060","article-title":"Effect of plasmapheresis for acute humoral rejection after heart transplantation.","volume":"38","author":"Wang","year":"2006","journal-title":"Transplant Proc"},{"key":"R57-20250404","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1111\/j.1399-3046.2012.01690.x","article-title":"Cardiac antibody-mediated rejection.","volume":"16","author":"Chin","year":"2012","journal-title":"Pediatr Transplant"},{"key":"R58-20250404","first-page":"301","article-title":"Heart transplant rejection treated with plasmapheresis.","volume":"11","author":"Partanen","year":"1992","journal-title":"J Heart Lung Transplant"},{"key":"R59-20250404","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1016\/j.transproceed.2012.01.086","article-title":"Steroid pulse therapy combined with plasmapheresis for clinically compromised patients after heart transplantation.","volume":"44","author":"Chou","year":"2012","journal-title":"Transplant Proc"},{"key":"R60-20250404","doi-asserted-by":"crossref","first-page":"e14454","DOI":"10.1111\/ctr.14454","article-title":"Eculizumab for antibody-mediated rejection in heart transplantation: a case-control study.","volume":"35","author":"Kittleson","year":"2021","journal-title":"Clin Transplant"},{"key":"R61-20250404","doi-asserted-by":"crossref","first-page":"2479","DOI":"10.1111\/ajt.16420","article-title":"Complement inhibition for prevention of antibody-mediated rejection in immunologically high-risk heart allograft recipients.","volume":"21","author":"Patel","year":"2021","journal-title":"Am J Transplant"},{"key":"R62-20250404","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1097\/MOT.0000000000000249","article-title":"Eculizumab use in kidney transplantation.","volume":"20","author":"Johnson","year":"2015","journal-title":"Curr Opin Organ Transplant"},{"key":"R63-20250404","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.trre.2013.04.002","article-title":"Eculizumab in renal transplantation.","volume":"27","author":"Legendre","year":"2013","journal-title":"Transplant Rev"},{"key":"R64-20250404","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1056\/NEJMoa2028700","article-title":"Tocilizumab in hospitalized patients with severe COVID-19 pneumonia.","volume":"384","author":"Rosas","year":"2021","journal-title":"N Engl J Med"},{"key":"R65-20250404","doi-asserted-by":"crossref","first-page":"S38","DOI":"10.1016\/j.healun.2019.01.079","article-title":"Tocilizumab for antibody-mediated rejection in the setting of cardiac allograft vasculopathy.","volume":"38","author":"January","year":"2019","journal-title":"J Heart Lung Transplant"},{"key":"R66-20250404","doi-asserted-by":"crossref","first-page":"S339","DOI":"10.1016\/j.healun.2022.01.1402","article-title":"Efficacy of tocilizumab for refractory sensitized patients awaiting heart transplantation.","volume":"41","author":"Deen","year":"2022","journal-title":"J Heart Lung Transplant"}],"container-title":["Cardiology in Review"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/CRD.0000000000000596","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T16:59:57Z","timestamp":1786035597000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/CRD.0000000000000596"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,2]]},"references-count":61,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/crd.0000000000000596","relation":{},"ISSN":["1538-4683"],"issn-type":[{"value":"1538-4683","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,2]]}}}